Table 2.
Clinical characteristics of the participants with T2D according to hemoglobin A1c levels.
| Hemoglobin A1c (%) | <7%(n = 39) | ≥7%(n = 55) | P |
|---|---|---|---|
| Age | 59.1 ± 7.1 | 58.0 ± 8.7 | 0.53 |
| BMI | 36.2 ± 4.9 | 36.2 ± 6.0 | 0.94 |
| Duration of T2D (years) | 4.1 ± 3.8 | 8.7 ± 5.7 | 0.0002 |
| Use of medication for T2D | 25/38 | 53/55 | 0.0001 |
| Whole Body BMD (g/cm2) | 1.171 ± 0.104 | 1.145 ± 0.110 | 0.11 |
| Lumbar spine BMD (g/cm2) | 1.155 ± 0.149 | 1.125 ± 0.167 | 0.50 |
| Total hip BMD (g/cm2) | 1.108 ± 0.106 | 1.117 ± 0.135 | 0.80 |
| Femoral neck BMD (g/cm2) | 0.871 ± 0.127 | 0.882 ± 0.150 | 0.58 |
| osteocalcin (ng/ml) | 5.90 ± 2.66 | 3.90 ± 2.64 | 0.001 |
| CTx (ng/ml) | 0.28 ± 0.16 | 0.18 ± 0.12 | 0.002 |
| Sclerostin (ng/ml) | 0.80 ± 0.24 | 0.75 ± 0.21 | 0.34 |
| Testosterone (ng/dl) | 276.7 ± 117.7 | 275.7 ± 81.6 | 0.96 |
| Estradiol (pg/ml) | 22.0 ± 18.2 | 22.2 ± 14.6 | 0.97 |
| 25-hydroxyvitamin D (ng/ml) | 25.0 ± 8.9 | 25.9 ± 11.6 | 0.72 |
| PTH (pg/ml) | 53.8 ± 20.0 | 47.4 ± 29.7 | 0.30 |
BMI, body mass index; T2D, type 2 diabetes mellitus, CTx, C-telopeptide; SCL, Sclerostin; BMD, bone mineral density; PTH, parathyroid hormone; p-values for BMD are adjusted for age, BMI and testosterone levels. Bolded p-values are significant.